Status:
RECRUITING
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
Lead Sponsor:
Grupo Argentino de Tratamiento de la Leucemia Aguda
Collaborating Sponsors:
Takeda
Conditions:
Hodgkin Lymphoma, Adult
Relapsed Hodgkin's Disease, Adult
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicenter, observational real world study with prospective follow up that will evaluate the treatment approach in patients with relapsed/refractory cHL who undergo ASCT in Argentina.
Detailed Description
The purpose of the study is to gather real world evidence of the proportion and characteristics of patients with relapsed refractory cHL who undergo ASCT, who receive consolidation with BV, and to stu...
Eligibility Criteria
Inclusion
- Patients 18 years or older.
- All patients with histologically confirmed cHL who are primary refractory or relapse and receive ASCT as part of their salvage therapy.
- Signature of the form consent for participation in the study.
Exclusion
- Patients with Relapsed/Refractory cHL not suitable for ASCT.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04776265
Start Date
June 1 2021
End Date
April 1 2024
Last Update
January 9 2024
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Nacional Posadas
El Palomar, Buenos Aires, Argentina
2
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina
3
Hospital de Alta Complejidad El Cruce
San Juan Bautista, Buenos Aires, Argentina
4
Hospital San Martín
Paraná, Entre Ríos Province, Argentina